Evidence map›Paper›PMID 30066148›Full record

Trial reportDiabetologia2018

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.

Naveed Sattar, David Fitchett, Stefan Hantel, Jyothis T George, Bernard Zinman

Open access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 6 pooled it
14.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 6 syntheses or guidelines pooled it, 161 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Naveed SattarBritish Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK. naveed.sattar@glasgow.ac.uk.
David FitchettSt Michael's Hospital, Division of Cardiology, University of Toronto, Toronto, ON, Canada.
Stefan HantelBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Jyothis T GeorgeBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Bernard ZinmanLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
Boehringer Ingelheim (Germany) · DESt. Michael's Hospital · CAUniversity of Glasgow · GBUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisIn addition to beneficial effects on glycaemia and cardiovascular death, empagliflozin improves adiposity indices. We investigated the effect of empagliflozin on aminotransferases (correlates of liver fat) in individuals with type 2 diabetes.

methodsChanges from baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were assessed in the EMPA-REG OUTCOME

resultsIn the EMPA-REG OUTCOME CONCLUSIONS/

interpretationThese highly consistent results suggest that empagliflozin reduces aminotransferases in individuals with type 2 diabetes, in a pattern (reductions in ALT>AST) that is potentially consistent with a reduction in liver fat, especially when ALT levels are high.

Indexed as

Adipose TissueAsian PeopleAspartate AminotransferasesBenzhydryl CompoundsDiabetes Mellitus, Type 2FemaleGlucosidesHumansHypoglycemic AgentsLiverMaleNon-alcoholic Fatty Liver DiseaseResearch DesignSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsSulfonylurea CompoundsAspartate AminotransferasesBenzhydryl CompoundsempagliflozinglimepirideGlucosidesHypoglycemic AgentsSLC5A2 protein, humanSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsSulfonylurea CompoundsTransaminasesAlanine aminotransferaseAspartate aminotransferaseNon-alcoholic fatty liver diseaseSodium glucose cotransporter 2 inhibitionType 2 diabetes mellitus

Identifiers

PMID30066148
PMCPMC6133166
OpenAlexW2887583392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.